Text Size:AAA

OX40/TNFRSF4/CD134  Protein, Antibody, ELISA Kit, cDNA Clone

製品の説明: Active  
発現宿主: Human Cells  
  • Slide 1
10481-H08H-50
10481-H08H-100
50 µg 
100 µg 
Add to Cart
発現宿主: Human Cells  
  • Slide 1
10481-H03H-50
10481-H03H-100
50 µg 
100 µg 
Add to Cart
発現宿主: Human Cells  
  • Slide 1
50808-M02H-50
50808-M02H-100
50 µg 
100 µg 
Add to Cart
発現宿主: Human Cells  
  • Slide 1
90846-C02H-50
90846-C02H-200
50 µg 
200 µg 
Add to Cart
発現宿主: Human Cells  
  • Slide 1
90846-C08H-50
90846-C08H-200
50 µg 
200 µg 
Add to Cart

OX40/TNFRSF4/CD134 Related Area

OX40/TNFRSF4/CD134 関連経路

OX40/TNFRSF4/CD134 関連製品

OX40/TNFRSF4/CD134 関連製品

Featured Reagent Products

OX40/TNFRSF4/CD134 サマリー & タンパク質情報

OX40/TNFRSF4/CD134 関連情報

OX40/TNFRSF4/CD134 背景

遺伝子の概要: OX40, the protein encoded by this TNFRSF4 gene is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. Knockout studies in mice suggested that OX40 promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. The knockout studies also suggested the roles of this receptor in CD4+ T cell response, as well as in T cell-dependent B cell proliferation and differentiation.
General information above from NCBI
サブユニット構造: Interacts with TRAF2, TRAF3 and TRAF5. {ECO:0000269|PubMed:16905106, ECO:0000269|PubMed:9418902, ECO:0000269|PubMed:9488716}.
細胞内位置: Membrane; Single-pass type I membrane protein.
疾患関連性: DISEASE: Immunodeficiency 16 (IMD16) [MIM:615593]: An autosomal recessive primary immunodeficiency associated with classic Kaposi sarcoma of childhood and poor T-cell recall immune responses due to complete functional OX40 deficiency. {ECO:0000269|PubMed:23897980}. Note=The disease is caused by mutations affecting the gene represented in this entry.
シーケンスの類似性: Contains 4 TNFR-Cys repeats. {ECO:0000255|PROSITE-ProRule:PRU00206}.
General information above from UniProt

OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease.

Immune Checkpoint
Immune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies   Immune Checkpoint Detection: WB Antibodies
Immune Checkpoint Proteins
Immune Checkpoint Targets   Co-stimulatory Immune Checkpoint Targets

Immunotherapy   Cancer Immunotherapy   Targeted Therapy

OX40/TNFRSF4/CD134 代替名

OX40/TNFRSF4/CD134 関連研究

  • Compaan D.M., et al. (2006) .The crystal structure of the costimulatory OX40-OX40L complex. Structure 14:1321-1330.
  • Kawamata S., et al. (1998) .Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J. Biol. Chem. 273:5808-5814.
  • Byun M., (2013) Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J. Exp. Med. 210:1743-1759.
  • 注意:すべての製品は、"研究目的のみに使用するものであり、診断または治療目的に使用するものではありません"